Compugen Publishes Paper in Cancer Immunology Research on Unique Biology of PVRIG and its Therapeutic Potential

Core Insights - Compugen Ltd. has published a peer-reviewed paper on the immune checkpoint PVRIG, highlighting its expression on stem-like T cells in tumors and its potential role in enhancing immune infiltration in non-inflamed tumors [1][2] - The company has demonstrated that the triple blockade of PVRIG, TIGIT, and PD-1 pathways using its antibody COM701 shows durable clinical responses and a favorable safety profile in typically non-responsive indications [2] - Compugen is advancing its pipeline with two proprietary product candidates, COM701 and COM902, targeting PVRIG and TIGIT respectively, and has a partnered program in Phase 3 development with AstraZeneca [3] Company Overview - Compugen is a clinical-stage therapeutic discovery and development company focused on cancer immunotherapies, utilizing predictive computational discovery to identify new drug targets [3] - The company’s pipeline includes COM503, a potential first-in-class antibody in IND enabling studies, licensed to Gilead, which targets the interaction between IL-18 binding protein and IL-18 [3] - Compugen is headquartered in Israel and has offices in San Francisco, CA, with its shares listed on Nasdaq and the Tel Aviv Stock Exchange under the ticker symbol CGEN [3]